---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-117199"
form_type: "8-K"
ticker: "BGMS"
cik: "0001130166"
company_name: "Bio Green Med Solution, Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T04:37:42.822543+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cyclacel reports Q3 net loss of $6.1M; cash runway only through end of 2023

## Summary
- Cash equivalents $5.9M at Sep 30, 2023, down from $18.3M at Dec 31, 2022.
- Net loss of $6.1M for Q3 2023 vs $5.1M in Q3 2022; R&D spend rose to $5.2M.
- Available cash funds planned programs only through end of 2023; discretionary cuts could extend into Q2 2024.
- Fadraciclib dose escalation near RP2D selection; plogosertib recruiting at dose level 5 with epigenetic mechanism under study.
- UK R&D tax credits reduced to $0.6M in Q3 2023 from $1.0M due to legislative changes.

## SEC filing metadata
- accession: 0001104659-23-117199
- form_type: 8-K
- ticker: BGMS
- cik: 0001130166
- company_name: Bio Green Med Solution, Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130166/000110465923117199/0001104659-23-117199-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130166/000110465923117199/tm2330442d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-117199
- JSON: https://secwatch.observer/filing/0001104659-23-117199.json
- Plain text: https://secwatch.observer/filing/0001104659-23-117199.txt

## Key facts
- Earnings Releases
  Bio Green Med Solution, Inc. reported third quarter ended September 30, 2023 results: net income $6.1 million.
  - Period: third quarter ended September 30, 2023
  - Net income: $6.1 million
  - Result: reported results
  source text: Net loss for the three months ended September 30, 2023, was $6.1 million, compared to $5.1 million for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1130166/000110465923117199/0001104659-23-117199-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.